{"id":2613,"date":"2018-04-13T17:15:08","date_gmt":"2018-04-13T11:45:08","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=2613"},"modified":"2023-06-14T11:35:13","modified_gmt":"2023-06-14T06:05:13","slug":"chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment","title":{"rendered":"Chronic Inflammatory Demyelinating Polyneuropathy \u2013 lack of Effective treatment"},"content":{"rendered":"

Chronic inflammatory demyelinating polyneuropathy (CIDP)<\/strong><\/a> is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. The disease is a chronic form of acute inflammatory demyelinating polyneuropathy<\/a> (AIDP) which is the most common form of Guillain Barre Syndrome<\/a> (GBS) in the United States and Europe.<\/p>\n

CIDP affects about 8.9 per 100,000 people in the United States that can occur at any age in both genders. It is more common in young adults, and is observed mostly in males in comparison to women. The major symptoms of CIDP include slow progressive symmetric weakness of muscles around the hips and shoulder as well as impaired sensory function in the legs and arms. The motor and sensory impairments usually affect both sides of the body, and the degree of severity followed by the course of disease may vary from case to case.<\/p>\n

There are a number of IVIG (immunoglobulin) therapies available in the market which are approved by the regulatory bodies in the US, Europe and Japan. Recently in March 2018, The European Commission has granted marketing authorization to Hizentra for the treatment of CIDP. CSL Behring\u2019s Privigen (IV) and Hizentra (SC) are estimated to be the key market growth drivers with heavy demands. Most of the pipeline<\/a> therapeutic candidates are being actively developed by companies in the late stage of development. OctaPharma, Shire are some of the major companies which are developing CIDP targeted therapeutics in the late stage.<\/p>\n

Existing CIDP therapies are intravenous human immunoglobulins (IVIG), corticosteroids, plasma exchange and sometimes chronic immunosuppressive agents. These therapies improve strength, conveniently taken by mouth (inexpensive), but lack in limiting the side effects. New Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments.<\/p>\n

Yuktie<\/p>\n

Associate Analyst<\/p>\n","protected":false},"excerpt":{"rendered":"

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare neurological disorder which is described as the inflammation of nerve roots and peripheral nerves and destruction of the fatty protective covering (myelin sheath) over the nerves. The disease is a chronic form of acute inflammatory demyelinating polyneuropathy (AIDP) which is the most common form of Guillain Barre […]<\/p>\n","protected":false},"author":1,"featured_media":2741,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":1,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[1118,1571,1574,1578,1575,204,1573,1572,1577,1029,1576,1230,706,852],"industry":[17225],"therapeutic_areas":[17245,17234],"class_list":["post-2613","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-business-research","tag-chronic-inflammatory-demyelinating-polyneuropathy","tag-cidp","tag-corticosteroids","tag-csl-behrings-privigen","tag-delveinsight","tag-demyelinating-polyneuropathy","tag-guillain-barre-syndrome","tag-intravenous-human-immunoglobulins-ivig","tag-market-report","tag-octapharma","tag-pharma-consultancy","tag-pharmaceutical-industry","tag-shire","industry-pharmaceutical","therapeutic_areas-neurology","therapeutic_areas-rare-diseases"],"acf":[],"yoast_head":"\nChronic Inflammatory Demyelinating Polyneuropathy-DELVEINSIGHT<\/title>\n<meta name=\"description\" content=\"Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective and specific.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chronic Inflammatory Demyelinating Polyneuropathy-DELVEINSIGHT\" \/>\n<meta property=\"og:description\" content=\"Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective and specific.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2018-04-13T11:45:08+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-14T06:05:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"785\" \/>\n\t<meta property=\"og:image:height\" content=\"441\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chronic Inflammatory Demyelinating Polyneuropathy-DELVEINSIGHT","description":"Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective and specific.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment","og_locale":"en_US","og_type":"article","og_title":"Chronic Inflammatory Demyelinating Polyneuropathy-DELVEINSIGHT","og_description":"Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective and specific.","og_url":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2018-04-13T11:45:08+00:00","article_modified_time":"2023-06-14T06:05:13+00:00","og_image":[{"width":785,"height":441,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment#article","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment"},"author":{"name":"DelveInsight","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"headline":"Chronic Inflammatory Demyelinating Polyneuropathy \u2013 lack of Effective treatment","datePublished":"2018-04-13T11:45:08+00:00","dateModified":"2023-06-14T06:05:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment"},"wordCount":325,"commentCount":0,"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441.jpg","keywords":["business research","Chronic Inflammatory Demyelinating Polyneuropathy","CIDP","corticosteroids","CSL Behring\u2019s Privigen","DelveInsight","demyelinating polyneuropathy","Guillain Barre Syndrome","intravenous human immunoglobulins (IVIG)","market report","OctaPharma","pharma consultancy","Pharmaceutical Industry","Shire"],"articleSection":["Articles"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment#respond"]}],"copyrightYear":"2018","copyrightHolder":{"@id":"https:\/\/www.delveinsight.com\/blog\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment","url":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment","name":"Chronic Inflammatory Demyelinating Polyneuropathy-DELVEINSIGHT","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441.jpg","datePublished":"2018-04-13T11:45:08+00:00","dateModified":"2023-06-14T06:05:13+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective and specific.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/chronic-inflammatory-demyelinating-polyneuropathy-lack-effective-treatment#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441.jpg","width":785,"height":441,"caption":"Chronic inflammatory demyelinating polyneuropathy therapies are required with novel and targeted mechanism of action that are more effective, specific, cost effective, and less toxic than existing available treatments."},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2018\/04\/09021726\/nerves785x441-300x169.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">business research<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Chronic Inflammatory Demyelinating Polyneuropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CIDP<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">corticosteroids<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">CSL Behring\u2019s Privigen<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">DelveInsight<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">demyelinating polyneuropathy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Guillain Barre Syndrome<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">intravenous human immunoglobulins (IVIG)<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">market report<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">OctaPharma<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">pharma consultancy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Shire<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">business research<\/span>","<span class=\"advgb-post-tax-term\">Chronic Inflammatory Demyelinating Polyneuropathy<\/span>","<span class=\"advgb-post-tax-term\">CIDP<\/span>","<span class=\"advgb-post-tax-term\">corticosteroids<\/span>","<span class=\"advgb-post-tax-term\">CSL Behring\u2019s Privigen<\/span>","<span class=\"advgb-post-tax-term\">DelveInsight<\/span>","<span class=\"advgb-post-tax-term\">demyelinating polyneuropathy<\/span>","<span class=\"advgb-post-tax-term\">Guillain Barre Syndrome<\/span>","<span class=\"advgb-post-tax-term\">intravenous human immunoglobulins (IVIG)<\/span>","<span class=\"advgb-post-tax-term\">market report<\/span>","<span class=\"advgb-post-tax-term\">OctaPharma<\/span>","<span class=\"advgb-post-tax-term\">pharma consultancy<\/span>","<span class=\"advgb-post-tax-term\">Pharmaceutical Industry<\/span>","<span class=\"advgb-post-tax-term\">Shire<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 8 years ago","modified":"Updated 3 years ago"},"absolute_dates":{"created":"Posted on Apr 13, 2018","modified":"Updated on Jun 14, 2023"},"absolute_dates_time":{"created":"Posted on Apr 13, 2018 5:15 pm","modified":"Updated on Jun 14, 2023 11:35 am"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2613","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=2613"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/2613\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/2741"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=2613"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=2613"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=2613"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=2613"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=2613"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}